Incidence of liver cancer in young adults according to the global burden of disease database 2019.


Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
08 Apr 2024
Historique:
received: 18 01 2024
accepted: 19 02 2024
medline: 10 4 2024
pubmed: 10 4 2024
entrez: 10 4 2024
Statut: aheadofprint

Résumé

The worldwide burden of cancer is increasing in younger populations. However, the epidemiology of primary liver cancer remains understudied in young adults compared to other cancer forms. This study analyzed data from the Global Burden of Disease (GBD) study between 2010 and 2019 to assess the age-standardized incidence, mortality, and disability-adjusted life years (DALYs) associated with primary liver cancer in the young (15-49 y), stratified by region, nation, sociodemographic index, and sex. The study found a global estimate of 78,299 primary liver cancer cases, 60,602 deaths, and 2.90 million DALYs in the young population. The Western Pacific region exhibited the highest burden in 2019, showing the most significant increase compared to other regions between 2010-2019. More than half of countries worldwide have undergone an increase in primary liver cancer incidence rates in young adults. Around 12.51% of deaths due to primary liver cancer occur in young individuals. Throughout the study period, there was a significant decline in primary liver cancer mortality due to most etiologies, except for metabolic dysfunction-associated steatotic liver disease (MASLD)-attributable primary liver cancer (annual percentage change [APC] +0.87%, 95% confidence interval 0.70-1.05%) and alcohol-attributable primary liver cancer (APC +0.21%, 95% confidence interval 0.01-0.42%). Limitations of the GBD database include reliance on the quality of primary data and possible underestimation of alcohol consumption. Over the past decade, there has been a marked increase in the burden of primary liver cancer, especially that originating from steatotic liver disease. This trend calls for the development of urgent and comprehensive strategies to mitigate this rising burden globally.

Identifiants

pubmed: 38598364
doi: 10.1097/HEP.0000000000000872
pii: 01515467-990000000-00835
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Association for the Study of Liver Diseases.

Auteurs

Pojsakorn Danpanichkul (P)

Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Majd B Aboona (MB)

Department of Internal Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.

Banthoon Sukphutanan (B)

Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Siwanart Kongarin (S)

Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Kwanjit Duangsonk (K)

Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Cheng Han Ng (CH)

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.

Mark D Muthiah (MD)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Daniel Q Huang (DQ)

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
MASLD Research Center, Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.

Yuya Seko (Y)

Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto, 602-8566, Japan.

Luis Antonio Díaz (LA)

Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago,Chile.
Observatorio Multicéntrico de Enfermedades Gastrointestinales, OMEGA, Santiago, Chile.

Juan Pablo Arab (JP)

Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago,Chile.
Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada.
Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Ontario, Canada.

Ju Dong Yang (JD)

Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Vincent L Chen (VL)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Donghee Kim (D)

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.

Mazen Noureddin (M)

Houston Research Institute and Houston Methodist Hospital, Houston, Texas, USA.

Suthat Liangpunsakul (S)

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.

Karn Wijarnpreecha (K)

Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine and Division of Gastroenterology and Hepatology, Phoenix, Arizona, USA.
Department of Internal Medicine, Banner University Medical Center, Phoenix, Arizona, USA.
BIO5 Institute, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.

Classifications MeSH